Secondary Logo

Journal Logo

Letters to the Editor

The Incidence Rates and Standardized Incidence Ratios of Cancer in Hemophilic HIV/AIDS Patients in Taiwan

Chen, Marcelo MD, PhD; Jen, Ian MD; Sharp, Gerald B. DrPH; Chen, Yi-Ming Arthur MD, ScD

Author Information
JAIDS Journal of Acquired Immune Deficiency Syndromes: April 1, 2016 - Volume 71 - Issue 4 - p e114-e115
doi: 10.1097/QAI.0000000000000903
  • Free

To the Editors:

Hemophilic HIV/AIDS patients have been regarded as one of the best cohorts to study the natural history of HIV infection since the time of seroconversion in most of the infections can be ascertained.1 Before 1985, many hemophiliacs were unknowingly treated with factor XIII or factor IX concentrates contaminated with HIV.2 Advances in factor replacement therapy have allowed hemophiliacs to reach an older age.3 Therefore, age-related diseases such as cancer have increasingly been recognized.4 Similarly, highly active antiretroviral therapy has improved survival in people living with HIV/AIDS.5–9 We previously reported an increased incidence of cancers in a nationwide registry of 15,269 HIV/AIDS patients in Taiwan during 1998–2009.10 Excluded from that cohort were HIV/AIDS patients with hemophilia because it has been reported that they have significantly longer natural history and slower disease progression than other HIV/AIDS patients.11 In this study, we determined the cancer incidence density (ID) and standardized incidence ratio (SIR) among hemophilic HIV/AIDS patients using Taiwan's National Health Insurance Research Database in a similar fashion as previously reported.10 All of the hemophiliacs in Taiwan contracted HIV-1 infection through unheated factor VIII blood products in 1983–1984.12 If we assume that they contracted hemophilia in June 1984, we can add 13.5 years per person to the calculation of person-years. The end date was December 31, 2009 or the date of death for each person who died during the follow-up period. The ID of each type of cancer after HIV infection was calculated by dividing the number of observed cancer cases by the total person-years at risk for that cancer. The SIR for each cancer type was calculated by dividing the observed number of cases by the number that would be expected if age-specific, sex-specific, and calendar period–specific rates of the comparison population applied.13 The 95% confidence interval was calculated by Poisson distribution. All analyses were conducted using SAS version 9.2 (SAS Institute Inc., Cary, NC). A 2-tailed P value of less than 0.05 was considered statistically significant.

A total of 34 hemophilic HIV/AIDS patients contributed 736.72 person-years. The mean age of the patients was 34.3 ± 14.0 years (range, 15–85 years). Eight of these patients were subsequently diagnosed with cancer (Table 1). The highest ID was seen in cancers of the oral cavity (ID = 542.95/100,000 person-years), which includes cancers of the oral cavity, oropharynx, hypopharynx, and larynx, followed by non-Hodgkin lymphoma (ID = 407.21/100,000 person-years). When compared with the general population, increased SIRs were seen in hemophilic HIV patients with non-Hodgkin lymphoma and cancers of the oral cavity. When compared with the total HIV cohort, increased SIR was seen in hemophilic HIV/AIDS patients with cancers of the oral cavity (SIR = 3.76, 95% confidence interval: 1.01 to 9.64).

Incidence Density and Standardized Incidence Rate of Cancers in Hemophilic HIV Patients Compared With the General Population and Nonhemophilic HIV/AIDS Cohort

Hemophilia is presumed to have a protective effect against cancer spread and dissemination through decreased dissemination of thrombin; however, the substitution of coagulation factor may increase cancer rates.14 A previous study by Rabkin et al15 in 1992 showed that with the exception of Kaposi sarcoma and non-Hodgkin lymphoma, cancer incidence was not increased in hemophilic HIV-positive patients compared with the general population of the United States. Similar results were also seen in an Italian study by Tagliaferri et al16 Our study showed that hemophilic HIV-positive patients were also at an increased risk of cancers of the oral cavity, oropharynx, hypopharynx, and larynx when compared with the general population of Taiwan.

Our study also showed an increased risk of oral cavity cancers in the hemophilic HIV/AIDS patients compared with the general HIV/AIDS cohort. This may partly be explained by increased case surveillance and ascertainment in hemophiliacs. Further studies in HIV-negative hemophiliacs and according to the severity of hemophilia are warranted to elucidate the association between hemophilia, HIV infection, and cancer.

With advances in factor replacement therapy and highly active antiretroviral therapy, the life expectancy of hemophilic HIV/AIDS patients is approaching that of the general population. Our results showed that cancer has become an important comorbidity in these HIV/AIDS patients with hemophilia and that they are at an increased risk of cancers when compared with nonhemophilic HIV/AIDS patients and the general population. More frequent screening for cancers is therefore recommended in hemophilic HIV/AIDS patients.


1. Eyster ME, Gail MH, Ballard JO, et al.. Natural history of human immunodeficiency virus infections in hemophiliacs: effects of T-cell subsets, platelet counts, and age. Ann Intern Med. 1987;107:1–6.
2. Evatt BL, Gomperts ED, McDougal JS, et al.. Coincidental appearance of LAV/HTLV-III antibodies in hemophiliacs and the onset of the AIDS epidemic. N Engl J Med. 1985;312:483–486.
3. Tagliaferri A, Rivolta GF, Iorio A, et al.. Mortality and causes of death in Italian persons with haemophilia, 1990-2007. Haemophilia. 2010;16:437–446.
4. Franchini M, Lippi G, Montagnana M, et al.. Hemophilia and cancer: a new challenge for hemophilia centers. Cancer Treat Rev. 2009;35:374–377.
5. Hogg RS, Heath KV, Yip B, et al.. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA. 1998;279:450–454.
6. Mocroft A, Phillips AN, Friis-Moller N, et al.. Response to antiretroviral therapy among patients exposed to three classes of antiretrovirals: results from the EuroSIDA study. Antivir Ther. 2002;7:21–30.
7. Palella FJ Jr, Baker RK, Moorman AC, et al.. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006;43:27–34.
8. Palella FJ Jr, Delaney KM, Moorman AC, et al.. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853–860.
9. d'Arminio Monforte A, Sabin CA, Phillips A, et al.. The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy. Arch Intern Med. 2005;165:416–423.
10. Chen M, Jen I, Chen YH, et al.. Cancer incidence in a nationwide HIV/AIDS patient cohort in taiwan in 1998-2009. J Acquir Immune Defic Syndr. 2014;65:463–472.
11. Lorenzo JI, Moscardo F, Lopez-Aldeguer J, et al.. Progression to acquired immunodeficiency syndrome in 94 human immunodeficiency virus-positive hemophiliacs with long-term follow-up. Haematologica. 2001;86:291–296.
12. Shen MC, Hu FC, Lin JS, et al.. A longitudinal study of immunological status in Chinese hemophiliacs: importance of the heat viral inactivation of factor concentrates. I. Immunological associations with the consumption of factor concentrates. Haemophilia. 1995;1:243–248.
13. Breslow NE, Day NE. Statistical methods in cancer research. Volume II–the design and analysis of cohort studies. IARC Sci Publ. 1987:1–406.
14. Miesbach W, Seifried E. Does haemophilia influence cancer-related mortality in HIV-negative patients? Haemophilia. 2011;17:55–60.
15. Rabkin CS, Hilgartner MW, Hedberg KW, et al.. Incidence of lymphomas and other cancers in HIV-infected and HIV-uninfected patients with hemophilia. JAMA. 1992;267:1090–1094.
16. Tagliaferri A, Di Perna C, Santoro C, et al.. Cancers in patients with hemophilia: a retrospective study from the Italian Association of Hemophilia Centers. J Thromb Haemost. 2012;10:90–95.
Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.